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Cecilia Gabriel3, Elisabeth Mocaër3, Peter Meerlo1 & Eddy A. Van der Zee1
1Department of Molecular Neurobiology, University of Groningen, The Netherlands
2Department of Psychiatry, University of Groningen, The Netherlands
3Institut de Recherches Internationales Servier, Courbevoie, France
Keywords
Affective disorders; Chronic footshock stress;
c-Fos; DCX; Hippocampal cell proliferation;
Hippocampal cell survival; HPA-axis.
Correspondence
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Agomelatine is a novel antidepressant which acts as a melatonergic
(MT1/MT2) receptor agonist and serotonergic (5-HT2C) receptor antagonist.
The antidepressant properties of agomelatine have been demonstrated in ani-
mal models as well as in clinical studies. Several preclinical studies reported
agomelatine-induced effects on brain plasticity, mainly under basal condi-
tions in healthy animals. Yet, it is important to unravel agomelatine-mediated
changes in the brain affected by psychopathology or exposed to conditions
that might predispose to mood disorders. Since stress is implicated in the
etiology of depression, it is valid to investigate antidepressant-induced ef-
fects in animals subjected to chronic stress. In this context, we sought to
determine changes in the brain after agomelatine treatment in chronically
stressed rats. Adult male rats were subjected to footshock stress and agome-
latine treatment for 21 consecutive days. Rats exposed to footshock showed a
robust increase in adrenocorticotropic hormone (ACTH) and corticosterone.
Chronic agomelatine treatment did not markedly influence this HPA-axis
response. Whereas chronic exposure to daily footshock stress reduced c-
Fos expression in the hippocampal dentate gyrus, agomelatine treatment re-
versed this effect and normalized neuronal activity to basal levels. Moreover,
chronic agomelatine administration was associated with enhanced hippocam-
pal cell proliferation and survival in stressed but not in control rats. Fur-
thermore, agomelatine reversed the stress-induced decrease in doublecortin
expression in the dentate gyrus. Taken together, these data show a benefi-
cial action of agomelatine in the stress-compromised brain, where it restores
stress-affected hippocampal neuronal activity and promotes adult hippocampal
neurogenesis.
Introduction
Affective disorders, such as major depression, represent
a serious health problem with long-lasting consequences
for both patients and society [1]. Antidepressants, firstly
discovered by serendipity, revolutionized the treatment
of mood disorders [2]. Yet, more than half a century
later, the treatment of these disorders remains a chal-
lenge. Only about 50% of depressed patients treated with
currently available medications achieve complete remis-
sion [3,4]. Moreover, rather poor tolerability of antide-
pressant drugs and late onset of their therapeutic effects
further increase the risk of unsuccessful treatment [5].
Altogether, this urges the introduction of newer medica-
tions with fundamentally different mechanisms of action
than the older agents.
Agomelatine is a novel antidepressant which acts as
a potent melatonergic (MT1 and MT2) receptor agonist
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[6] and serotonergic (5-HT2C) receptor antagonist [7].
Current literature indicates that the therapeutic actions
of agomelatine are mediated at least partly through dif-
ferent mechanisms than selective serotonin reuptake in-
hibitors (SSRI) or tricyclics [8]. For example, some of its
effects may involve modulation of circadian rhythms and
changes in sleep–wake cycle [9,10]. The antidepressant
properties of agomelatine have been demonstrated both
in animal models [11–14] and in clinical studies [15–19].
Yet, the effects of agomelatine merit further investigation.
Beneficial effects of antidepressant drugs are observed
in depressed patients but not in healthy volunteers, sug-
gesting that the neurochemical effects of antidepressants
might differ in disturbed versus intact systems [5]. There-
fore, it is important to unravel agomelatine-mediated
changes in the brain affected by psychopathology (clinical
studies) or exposed to conditions that might predispose
to mood disorders (animal models). It therefore seems
a suitable approach to apply agomelatine treatment in
chronically stressed animals, in order to reliably explore
its beneficial actions and mechanisms behind them.
Stress, especially when severe and prolonged, is one
of the major predisposing risk factors for developing de-
pression [20,21]. Animal models of chronic stress provide
a valuable tool to investigate behavioral, endocrine and
neurobiological changes underlying stress-related psy-
chopathologies and mechanism of antidepressant ther-
apies [2,22]. Such models have revealed a variety of
stress-induced effects in the brain, such as impaired
neurotrophin signaling [23,24], atrophy of hippocampal
CA3 pyramidal neurons [25], reduced synaptic plasticity
[26], and suppressed neurogenesis in the dentate gyrus
[27,28]. Together, these changes have been suggested
to play a role in the development of neuronal dysfunc-
tions and ultimately increase one’s vulnerability to psy-
chopathology [29]. One of the brain areas particularly
sensitive to stress is the hippocampus, a region involved
in cognition, mood, and neuroendocrine stress reactivity.
There is a large body of data supporting the notion that
the hippocampus plays a role in depression and the action
of antidepressant drugs [30]. The hippocampus is also one
of the few regions of the brain where new neurons are
generated in adulthood [31,32]. Hippocampal neurogen-
esis has been established in several different species [33],
including primates [34] and humans [35]. During the last
decade, numerous studies focused on the hypothesis that
changes in hippocampal neurogenesis and plasticity in
general contribute to the etiology of depression as well as
to the action of antidepressant drugs [36–40]. Preclinical
studies suggest that antidepressants may exert their ther-
apeutic effects by enhancing neurotrophin signaling and
promoting the formation of new hippocampal neurons
as well as new synaptic connections in the brain [41,42].
Such effects have been described for many antidepressant
treatments, including serotonin- and norepinephrine-
enhancing drugs [43,44], electroconvulsive seizures [45],
and lithium [46]. In agreement with this, also the novel
antidepressant agomelatine promotes hippocampal neu-
rogenesis under basal conditions [47,48].
In the present study, we used a chronic footshock
stress model in order to test the effects of agomela-
tine under conditions of severe and prolonged stress.
This footshock model was previously shown to promote
HPA-axis hyperactivity, induce robust changes in gene
expression in stress-related brain areas, target intracellu-
lar signaling cascades involved in neuronal plasticity, and
affect hippocampal neurogenesis [49–54]. Here we inves-
tigated whether treatment with agomelatine is effective
in the brain, exposed to chronic stress. First, we examined
whether daily treatment with agomelatine for 21 consec-
utive days changed HPA-axis reactivity, induced by foot-
shock stress. Then, in order to gain further insight in the
processes targeted by stress and antidepressant therapy,
we investigated whether agomelatine induced changes in
neuronal activity as well as hippocampal neurogenesis.
Experimental Procedures
Animals and Housing
The experiments were performed using adult (10–12
weeks of age) male Wistar rats (Harlan, Horst, The
Netherlands) weighing 300–350 g at the beginning of
the experiment. The animals were housed individually
in a climate-controlled room with constant temperature
(21 ± 1 ◦C) and a 12 h light/12 h dark cycle (lights on
at 06:00 h). Food and water was available ad libitum.
The experiments were approved by the ethical commit-
tee for the use of experimental animals of the University
of Groningen and carried out in accordance with the Eu-
ropean Communities Council Directive of 24 November
1986 (86/609/EEC).
Experimental Protocol
Four groups of rats were used for the present exper-
iments: two groups of home-cage control rats (CTR),
which were treated either with vehicle (CTR-Veh) or
agomelatine (CTR-Ago), and two groups of chronically
stressed rats (STR), which were also treated either with
vehicle (STR-Veh) or agomelatine (STR-Ago). Each group
consisted of 8 animals. The home-cage control rats were
sacrificed concomitantly with the stressed rats which
were euthanized 24 h after the last footshock exposure.
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G. Dagytė et al. Neurobiological Effects of Agomelatine
Stress Procedure
During a 2-week acclimatization period before the start of
the experiments, all rats were weighed and handled daily.
Footshock stress was applied in a footshock box with a
grid floor connected to a shock generator and scrambler
[49,53]. Stress group rats were subjected to a daily session
of footshock stress for 21 consecutive days. During the
session in the footshock box rats received 5 uncontrol-
lable and inescapable footshocks (0.8 mA in intensity and
8 seconds in duration). All footshock sessions took place
during the light phase. In order to increase unpredictabil-
ity and minimize habituation, both timing and duration
of footshock sessions as well as intervals between shocks
within a session varied randomly (session starting time:
between 08:00 and 13:00 h; session duration: 15–80 min;
shock interval: 1–15 min), with the exception of the ses-
sions on days 1, 11, and 21. On these days, all animals
received footshock sessions of 20 min with shock inter-
vals of 5 min to allow standardized neuroendocrine mea-
surements. Control rats stayed undisturbed in their home
cages throughout the experiment.
Drug Treatment
One percent hydroxyethylcellulose (HEC) was used as a
vehicle for agomelatine delivery. Agomelatine solution
was prepared every day by dissolving agomelatine pow-
der in 1% HEC at a concentration of 40 mg/mL. The
choice of the agomelatine dose was made on the ba-
sis of its activity at this concentration in animal models
of depression and anxiety [12,55], and on neurogenesis
[47,48]. Rats were injected intraperitoneally either with
agomelatine (40 mg/kg) or vehicle daily at 16:00 (2 h
prior to the dark phase) for 21 days.
Neuroendocrine Measurements
In order to determine activation of the HPA-axis by foot-
shock stress and changes herein during the experiment,
blood samples were collected by tail bleeding and ana-
lyzed for adrenocorticotropic hormone (ACTH) and cor-
ticosterone [56]. Blood was collected on days 1, 11, and
21 of the chronic stress period. Each time, three samples
were taken from all stress group rats: baseline (before the
footshock procedure), stress (at the end of the 20-min
footshock session), and recovery (30 min after the ses-
sion in the footshock box). Home-cage control rats were
sampled once at the beginning of the light phase, simul-
taneously with the stress group rats. Blood samples were
collected in microcentrifuge tubes containing ethylenedi-
aminetetraacetic acid (EDTA) as the anticoagulant, and
kept on ice. Then, blood was centrifuged at 2600 × g
for 15 min and the supernatant stored at −80◦C until
radioimmunoassay measurements of ACTH and corticos-
terone were performed.
BrdU Labeling
In order to study survival of newly born cells in the hip-
pocampus during the experiment, rats received an injec-
tion of bromodeoxyuridine (BrdU: Sigma, St. Louis, MO,
USA), a synthetic analogue of thymidine which is incor-
porated into newly synthesized DNA of replicating cells
during the S phase of the cell cycle [57]. New cells were
labeled 4 days before the start of the experiment with
a single intraperitoneal injection (300 mg/kg). This spe-
cific time-point of BrdU labeling for studying cell survival
was chosen since it was shown that labeled progenitor
cells stop proliferating after 4 days [58]. Such an injec-
tion schedule was similarly applied in our laboratory pre-
viously [53,59].
Brain Collection and Immunohistochemistry
At the end of the experiment, 24 h after the last stress
session and 18 h after the last agomelatine injection,
rats were anesthetized with sodium pentobarbital and
transcardially perfused with heparinized saline followed
by 4% paraformaldehyde solution in 0.1 M phosphate
buffer. Brains were extracted and postfixed in the same
solution overnight at 4◦C and subsequently cryoprotected
by immersion in a 30% buffered sucrose solution for up
to 48 h. Coronal serial sections of 30 μm were cut using a
cryostat and stored in 0.01 M phosphate-buffered saline
with 0.1% sodium azide at 4◦C until immunohistochem-
istry was performed.
In order to assess effects of agomelatine and chronic
footshock stress on different aspects of hippocampal neu-
rogenesis, immunohistochemistry for Ki-67, doublecortin
(DCX), and BrdU was performed. Ki-67 is a nuclear
protein which is expressed during all phases of the cell
cycle, except G0 [60], which would therefore give an in-
dication of cell proliferation on the last day of the experi-
ment. DCX protein is expressed in newly born cells from
1 day to about 4 weeks of age, and might therefore re-
veal sustained changes in the neurogenesis process and
its modulation [61,62]. Finally, since a pool of newborn
cells was labeled with an injection of BrdU 4 days prior to
the start of the experiment, BrdU immunostaining would
indicate changes in survival of new cells in the course of
the experiment.
Effects of agomelatine and chronic footshock stress on
neuronal activity were assessed by immunohistochem-
istry for the immediate early gene c-Fos [63,64].
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The immunostainings were performed on free-floating
sections under continuous mild agitation. BrdU immuno-
histochemistry required extra steps for DNA denatura-
tion. For this purpose, sections were exposed to 2× saline
sodium citrate (2×SSC) containing 50% formamide for
30 min at 65◦C, followed by a rinse with 2×SSC, incuba-
tion with 2 M HCl for 30 min at 37◦C and a washing step
with 0.1 M borate buffer. Brain sections for all four im-
munostainings were preincubated in 3% normal serum
and 0.1% TritonX-100, and then incubated with one of
the following antibodies for 60 h at 4◦C: primary mouse-
anti-Ki-67 (1:200; Monosan, Uden, The Netherlands),
goat-anti-DCX (1:1000; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), rat-anti-BrdU (1:800; Serotec, Ox-
ford, UK) or rabbit-anti-c-Fos (1:10000; Calbiochem,
Darmstadt, Germany). Subsequently, sections were
rinsed in 0.01 M Tris-buffered saline and incubated
for 2 h at room temperature with secondary biotiny-
lated goat-anti-mouse, rabbit-anti-goat, donkey-anti-rat
or goat-anti-rabbit antibody depending on the primary
antibody host (1:500 for all secondary antibodies, Jack-
son ImmunoResearch, Suffolk, UK). Then, avidin-biotin
complex (1:500, Vector ABC kit, Vector Laboratories,
Burlingame, CA, USA) was added for 2 h, after which
the staining was visualized with 1 mg/mL diaminobenzi-
dine and 0.003% H2O2. Thereafter, sections were rinsed,
mounted on slides, dehydrated, and coverslipped for mi-
croscopic analysis. Due to technical problems, brain sec-
tions of two animals were excluded from DCX and c-Fos
immunostainings.
Quantification
All analyses were performed by an observer blind to the
group assignment. Ki-67 and BrdU positive cells were
counted in the subgranular zone (SGZ) and granular
cell layer (GCL) of the dentate gyrus in every 12th sec-
tion of the hippocampus under 500× magnification. Im-
munopositive cells that were located one cell diameter
away from SGZ were also included in the analysis. The
number of immunopositive cells in each section was ex-
pressed relative to the length of the dentate gyrus in or-
der to correct for variation in size of the hippocampus
along the rostro-caudal axis of the brain. The length of
the dentate gyrus was measured by delineating the entire
SGZ in each hippocampus. DCX immunoreactivity (ir) in
cell bodies and dendrites of the newly generated cells was
measured by a previously described method [53]. Briefly,
optical density (OD) of DCX expression was measured
in the DG and corrected for nonspecific background la-
beling, which was measured in the corpus callosum. In
total, 7–8 sections per animal (Bregma –2.56 to –6.30,
according to the rat brain atlas, Paxinos & Watson, 2nd
edition) were analyzed by delineating a similarly sized
area covering the entire width of SGZ and GCL in each
hippocampus. Images were taken using a Leica charged-
coupled device digital camera mounted on a microscope
(DMIRB, Leica, Cambridge, UK) at 100× magnification.
The OD was expressed in arbitrary units corresponding
to gray levels using a Quantimet 550 image analysis sys-
tem (Leica). In all three stainings, dorsal and ventral hip-
pocampi were analyzed separately. When similar changes
in the dorsal and ventral parts of hippocampus were de-
tected, these data were pooled and effects in the entire
hippocampus were presented.
c-Fos positive cells were quantified in 3 hippocampal
regions of interest (ROI): CA1, CA3 and dentate gyrus
(DG). In total, 4–5 sections per animal (Bregma −2.56 to
−4.52, according to the rat brain atlas, Paxinos & Watson,
2nd edition) were analyzed by counting immunoreactive
cell nuclei in each ROI. Images were taken using a Leica
charged-coupled device digital camera mounted on a mi-
croscope (DMIRB, Leica) at 50× magnification. Positive
cell nuclei above the background threshold in each ROI
were counted using a Quantimet 550 image analysis sys-
tem (Leica) and the data were reported as the number of
positive cells/0.1 mm2.
Statistics
Two-way analysis of variance (ANOVA) was used to an-
alyze the effects of stress and agomelatine treatment on
hippocampal neurogenesis and neuronal activation. Re-
peated measures ANOVA was used to analyze the ACTH
and corticosterone responses in stress group animals, as
well as baseline values in both control and stress group
animals across 3 days. Food intake and body weight gain
data were analyzed by repeated measures ANOVA. When
appropriate, the Fisher LSD test was used for post-hoc
analysis.
Results
Food Intake and Body Weight
Food intake and body weight were measured from day
–4 to day 22 of the experiment. All rats ate and grew at
similar rates during the acclimatization period. Chronic
footshock stress reduced food intake (repeated measures
ANOVA, time × stress interaction: F(20,560) = 22.02,
P < 0.001), whereas agomelatine had no significant effect
(Figure 1A). In contrast, body weight gain was strongly
reduced by both chronic stress and agomelatine treat-
ment (repeated measures ANOVA, time × stress interac-
tion: F(20,560) = 21.51, P < 0.001; time × drug interaction:
F(20,560) = 9.55, P < 0.001; Figure 1B).
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Figure 1 Changes in cumulative food intake and body weight gain in rats
subjected to chronic stress and/or agomelatine treatment for 21 days.
Exposure to the footshock stress significantly reduced food intake in both
rats treated with agomelatine and vehicle (A). Both footshock stress and
agomelatine treatment significantly reduced body weight gain (B).
ACTH and Corticosterone Levels
Changes in plasma ACTH and corticosterone concentra-
tions in response to footshock exposure and agomelatine
treatment are shown in Figure 2. Baseline ACTH and cor-
ticosterone levels did not differ among the groups. As ex-
pected, footshock stress induced a robust HPA-axis acti-
vation (repeated measures ANOVA, stress effect: ACTH:
F(8,112) = 91.06, P < 0.001; CORT: F(8,112) = 111.31,
P < 0.001; stress vs. baseline: P < 0.001). The peak ACTH
levels in vehicle-treated animals on day 21 did not dif-
fer from the peak ACTH levels on day 1 and day 11 of
the experiment. In agomelatine-treated animals, the peak
ACTH levels on day 21 were significantly lower as com-
pared to the peak ACTH levels on day 1, but not day 11
of the experiment (repeated measures ANOVA, stress ×
drug interaction: F(8,112) = 2.39, P = 0.02; day 1-stress
vs. day 21-stress: P = 0.008; day 1-stress vs. day 11-stress
and day 11-stress vs. day 21-stress: P > 0.05). However,
there were no significant differences between the peak
ACTH levels of vehicle and agomelatine-treated rats on
any of the days tested (P > 0.05). There were no dif-
ferences in corticosterone response between vehicle and
agomelatine-treated rats at any time point.
Hippocampal Neuronal Activity
Figure 3 shows a representative example of c-Fos im-
munostaining in the hippocampus (A) with a higher
magnification of c-Fos-positive cells in the dentate gyrus
(B), CA3 (C), and CA1 (D) areas. Changes in basal
c-Fos expression in hippocampal subregions due to
chronic stress and agomelatine treatment are shown in
Figure 4. Two-way ANOVA revealed a significant drug
effect and a significant stress × drug interaction in c-
Fos-ir in the dentate gyrus (F(1,26) = 5.54, P = 0.03 and
F(1,26) = 13.76, P < 0.001, respectively; CTR Veh: 12.53 ±
1.06; STR Veh: 8.18 ± 0.74; CTR Ago: 11.46 ± 0.91; STR
Ago: 12.97 ± 0.29 c-Fos cells/0.1 mm2). Post-hoc Fisher
LSD test showed a significant chronic stress-induced de-
crease in c-Fos-ir in vehicle-treated animals (CTR Veh vs.
STR Veh: P < 0.001), which was reversed by agomelatine
treatment (STR Veh vs. STR Ago: P < 0.001). Although
similar changes in c-Fos-ir were noted in CA3 (CTR Veh:
4.58 ± 0.73; STR Veh: 2.32 ± 0.46; CTR Ago: 4.69 ± 0.46;
STR Ago: 4.25 ± 0.96 c-Fos cells/0.1 mm2) and CA1 (CTR
Veh: 2.04 ± 0.66; STR Veh: 1.14 ± 0.41; CTR Ago: 3.18 ±
0.55; STR Ago: 2.47 ± 0.72 c-Fos cells/0.1 mm2) areas of
hippocampus, they were not statistically significant (drug
effect and stress × drug interaction: P > 0.05).
Hippocampal Neurogenesis
Figure 5 shows representative examples of Ki-67 (A),
BrdU (B), and DCX (C) immunostainings in the hip-
pocampal dentate gyrus. Changes in various stages of hip-
pocampal neurogenesis after chronic stress and agome-
latine treatment are depicted in Figure 6. Hippocampal
cell proliferation was assessed by Ki-67 immunohisto-
chemistry (Figure 5A). Similar changes in proliferating
cell numbers were found in both dorsal (CTR Veh: 4.01 ±
0.35; STR Veh: 3.36 ± 0.23; CTR Ago: 4.31 ± 0.24; STR
Ago: 4.90 ± 0.29 Ki-67 cells/mm) and ventral dentate
gyrus (CTR Veh: 2.58 ± 0.23; STR Veh: 2.16 ± 0.11; CTR
Ago: 2.72 ± 0.31; STR Ago: 3.07 ± 0.18 Ki-67 cells/mm).
Therefore, these data were pooled in order to present ef-
fects in the entire hippocampus (Figure 6A). Two-way
ANOVA revealed a significant drug effect and a signifi-
cant stress × drug interaction in proliferating cell num-
bers (F(1,28) = 10.33, P = 0.003 and F(1,28) = 5.08, P =
0.03, respectively). Post-hoc Fisher LSD test showed that
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Figure 2 Plasma concentrations of ACTH and corticosterone in response
to footshock stress on days 1, 11, and 21 of the experiment. Since on day 1
blood was sampled before the drug treatment started, the data of rats as-
signed to either vehicle or agomelatine groups were pooled. Exposure to
the footshock significantly elevated both ACTH and corticosterone levels
as compared to baseline values (P < 0.001). Chronic agomelatine treat-
ment did not significantly influence either basal or stress-induced HPA-axis
activity.
agomelatine significantly increased the number of Ki-67-
positive cells in stressed animals (STR Veh vs. STR Ago,
P < 0.001), whereas it had no effect in control animals
(CTR Veh vs. CTR Ago, P > 0.05).
Hippocampal cell survival was assessed by BrdU im-
munohistochemistry (Figure 5B). Whereas no significant
effects were observed in the dorsal dentate gyrus (CTR
Veh: 4.26 ± 0.55; STR Veh: 4.08 ± 0.51; CTR Ago:
4.10 ± 0.33; STR Ago: 5.50 ± 0.60 BrdU cells/mm), a sig-
nificant stress × drug interaction was found in the ven-
tral dentate gyrus (Figure 6B; F(1,28) = 4.49, P = 0.04;
CTR Veh: 2.92 ± 0.40; STR Veh: 2.33 ± 0.20; CTR Ago:
2.46 ± 0.34; STR Ago: 3.45 ± 0.50 BrdU cells/mm). Post-
hoc Fisher LSD test showed that agomelatine significantly
increased the number of BrdU-positive cells in stressed
animals (STR Veh vs. STR Ago, P = 0.04), whereas it had
no effect in control animals (CTR Veh vs. CTR Ago, P >
0.05).
Effects of stress and agomelatine on newly born hip-
pocampal cell maturation were assessed by DCX label-
ing (Figure 5C). Similar changes in DCX expression were
found in both dorsal (CTR Veh: 0.31 ± 0.01; STR Veh:
0.27 ± 0.01; CTR Ago: 0.27 ± 0.01; STR Ago: 0.30 ± 0.01
DCX OD) and ventral dentate gyrus (CTR Veh: 0.32 ±
0.01; STR Veh: 0.28 ± 0.01; CTR Ago: 0.28 ± 0.01; STR
Ago: 0.32 ± 0.01 DCX OD). Therefore, these data were
pooled in order to present effects in the entire hippocam-
pus (Figure 6C). Two-way ANOVA revealed a significant
stress × drug interaction (F(1,26) = 29.39, P < 0.001).
Post-hoc Fisher LSD test showed that both chronic stress
and agomelatine reduced DCX expression in the dentate
gyrus (CTR Veh vs. STR Veh: P < 0.001; CTR Veh vs.
CTR Ago, P < 0.001). In stressed animals, agomelatine
reversed the decrease in DCX expression in the dentate
gyrus (STR Veh vs. STR Ago: P = 0.001).
Discussion
Agomelatine administered to chronically stressed rats in-
duced changes in the brain, extending from hippocam-
pal neuronal activity to adult neurogenesis. Whereas
chronic exposure to daily footshock stress reduced
200 CNS Neuroscience & Therapeutics 16 (2010) 195–207 c© 2010 The Authors Journal Compilation c© 2010 Blackwell Publishing Ltd
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Figure 3 A representative photomicrograph of c-Fos immunostaining in the hippocampus (A). Arrows point at c-Fos-positive cells in the dentate gyrus
(B), CA3 (C), and CA1 (D).
c-Fos expression in the dentate gyrus, agomelatine treat-
ment reversed this effect and normalized neuronal activ-
ity to basal levels. Chronic agomelatine also enhanced
hippocampal cell proliferation in rats concurrently ex-
posed to chronic stress and promoted survival of the
newly born cells selectively in the ventral hippocam-
pus. Finally, agomelatine treatment reversed the stress-
induced decrease in DCX expression. Taken together,
these data show that agomelatine is beneficial in the
stress-compromised brain. Our findings suggest that an-
tidepressant action of agomelatine may depend on its
ability to reverse stress-affected neuronal activity and
promote hippocampal neurogenesis.
Chronic footshock stress was associated with a sig-
nificant hypophagic effect, confirming the previous re-
ports on reduced body weight gain in stressed male rats
[49,53]. The 3-week treatment with agomelatine also led
to a reduction in growth, although a similar change in
body weight in rats of the same strain was not observed
in an earlier study after 7-week agomelatine treatment
[12]. Reductions in growth were also reported after SSRI
administration in rats, in which case it appeared to be a
result of decreased food intake [65,66]. However, agome-
latine administration in our study did not affect food
intake. Although agomelatine is not only a potent mela-
tonin receptor agonist but also acts as a 5-HT2C antag-
onist, the decrease in body weight is most likely a mela-
tonin receptor-mediated effect. In rodents, melatonin was
reported to decrease body weight without changes in food
intake, whereas different 5-HT2C antagonists were either
shown to increase it or to have no effect [67,68]. In con-
trast to the body weight decrease in rats, agomelatine
does not appear to affect body weight in monkeys and
humans [9,69].
Footshock stress has been shown to cause a severe ac-
tivation of the HPA-axis [53]. Pronounced increases in
both ACTH and corticosterone were observed here in re-
sponse to this form of stress. No habituation in the peak
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Figure 4 Effects of chronic stress and agomelatine treatment on basal
levels of c-Fos expression in hippocampal subregions. In the dentate gyrus,
a chronic stress-induced decrease in c-Fos-ir was reversed by agomelatine
treatment. Similar effects were noted in CA3 and CA1 regions of the
hippocampus, but they did not reach statistical significance. ∗∗∗P < 0.001.
responses was noted, even after 3 weeks of daily exposure
to footshock. Agomelatine treatment did not dramatically
influence either basal or stress-induced HPA-axis activity.
Our data are in line with previous reports where chronic
agomelatine had no effect on the HPA-axis parameters af-
ter immobilization stress in mice or after predator stress in
rats [13,70]. On the other hand, this antidepressant has
been shown to normalize stress-induced increase in cor-
tisol in the tree shrew model of chronic stress [71]. Dif-
ferences in the type of stressors and animal species used
might be responsible for this inconsistency.
Our c-Fos data suggest that agomelatine acts by nor-
malizing reduced neuronal activity in hippocampus, a
brain area sensitive to stress and often implicated in mood
disorders. It is interesting to note that whereas several
stress-related brain areas display increased c-Fos expres-
sion in response to repeated footshock stress, the den-
tate gyrus of the hippocampus is associated with reduced
activation of this immediate early gene [49,72]. Here,
we observed that such chronic stress-induced suppres-
sion of c-Fos expression in the dentate gyrus is prevented
by agomelatine treatment. Similar changes were noted
in CA3 and CA1 regions of the hippocampus, although
these did not reach statistical significance. The CA re-
gions showed fewer c-Fos-positive cells than the dentate
gyrus, which might have hampered the detection of sig-
nificant differences between the groups. The c-Fos induc-
tion reflects the functional activity of the neurons [64].
Therefore, alterations in neuronal activity may indirectly
indicate changes in hippocampal information processing.
Although the functional interpretation of c-Fos changes
deserves caution, it is tempting to speculate that by nor-
malizing stress-affected neuronal activity in the dentate
Figure 5 Representative photomicrographs of Ki-67 (A), BrdU (B), and
DCX (C) immunostainings in the hippocampal dentate gyrus. Arrows point
at Ki-67 (A), BrdU (B), and DCX (C) labeled cells.
gyrus, agomelatine may rescue the functional integrity of
hippocampal circuitry.
Prolonged footshock stress did not significantly affect
hippocampal cell proliferation or survival in our exper-
iment. The lack of significant stress-mediated effects on
these processes may depend on the timing of sacrifice
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Figure 6 Effects of chronic stress and agomelatine treatment on hip-
pocampal neurogenesis. Agomelatine promoted hippocampal cell prolif-
eration in stressed rats (A). A specific agomelatine-induced effect on cell
survival was observed in the ventral hippocampus (B). Both chronic stress
and agomelatine therapy reduced DCX expression in the dentate gyrus,
whereas a combination of stress and drug treatment reversed this effect
(C). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
of the animals as compared to the last stress session or
BrdU labeling. Animals were in fact euthanized 24 h af-
ter the final footshock session. This delay may be suffi-
cient to weaken the inhibitory influences of stress on cell
proliferation. A recent study revealed that chronic foot-
shock stress leads to short-lasting suppression of cell pro-
liferation which can easily go unnoticed if animals are
sacrificed 24 h after stress [53]. Interestingly, agomela-
tine promoted hippocampal cell proliferation and, to a
lesser extent, cell survival, in rats subjected to chronic
footshock stress. Whereas agomelatine-induced increase
in cell proliferation was observed in the entire hippocam-
pus, cell survival was selectively enhanced in the ventral
hippocampus, a region particularly involved in response
to stress and anxiety [73]. Current literature regard-
ing agomelatine-induced effects on hippocampal neuro-
genesis is scarce. Yet, it has been shown that 3-week
agomelatine treatment increased cell proliferation in the
ventral dentate gyrus of non-stressed Wistar rats,
whereas extending the treatment for additional 3 weeks
also promoted cell survival in the entire dentate gyrus
[47]. Agomelatine-mediated effect on hippocampal cell
proliferation was recently corroborated by another study,
which, in addition, reported that agomelatine administra-
tion for 15 or 21 days increased cell survival [48]. How-
ever, unpublished data suggest that 6-week agomelatine
treatment had no effect on cell survival in non-stressed
Sprague–Dawley rats [74]. Notably, our data indicate that
chronic agomelatine did not influence hippocampal cell
proliferation or survival in non-stressed rats. Discrepant
effects among studies may be due to subtle changes in the
experimental protocols, such as timing of BrdU injection
in relation to agomelatine administration and animal sac-
rifice. Group-housing conditions (three rats per cage) in
the experiments performed by the team of Daszuta might
also account for different outcomes in the rates of cell
proliferation and survival [47,48]. Recently, it has been
shown that social isolation affects hippocampal function
by decreasing expression of brain-derived neurotrophic
factor (BDNF) [75] and preventing or delaying exercise-
induced increase in neurogenesis [76,77]. In view of this,
the positive effect of agomelatine on cell proliferation
and survival might have been attenuated in our exper-
iment by the individual housing conditions. Neverthe-
less, agomelatine promoted hippocampal neurogenesis
in chronically stressed rats, confirming the previous ob-
servations on agomelatine’s action in animal models of
depression [74,78]. Although the agomelatine-induced
stimulation of hippocampal cell proliferation and survival
was rather mild, yet, it may indicate a compensatory pro-
cess, targeted at improving neuronal connectivity in the
brain affected by chronic stress.
In order to get more insight into agomelatine-induced
changes in hippocampal neurogenesis after chronic stress,
we examined the patterns of DCX expression in the den-
tate gyrus. Chronic footshock stress was associated with
a significant decline of DCX expression. Our previous
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study revealed that such a stress-induced reduction in
DCX labeling corresponds to a decreased number of DCX-
positive immature neurons [53]. Agomelatine also re-
duced DCX expression, which may depend on its abil-
ity to speed up the maturation of newly born cells [48]
and shortening in the time window of the expression of
this marker [47]. Interestingly, our data demonstrate that
such effects on DCX expression are negated when ani-
mals are exposed to both chronic stress and agomelatine
treatment. Agomelatine reversed the stress-induced re-
duction in DCX expression, suggesting a beneficial effect
of this novel antidepressant on neurogenesis despite the
concomitant stressful conditions.
It seems that regulation of DCX-positive cells by stress
and agomelatine is executed via different mechanisms.
DCX protein is transiently expressed during a period of
several weeks that extends from proliferative progeni-
tors to postmitotic neurons [79,80]. About 70% of DCX-
positive cells are postmitotic and represent young imma-
ture neurons, whereas about 20% are still in cell cy-
cle and the remaining 10% are progressing from late
neuroblasts to immature neurons [81]. It was proposed
that regulation of adult hippocampal neurogenesis pri-
marily occurs during the stages associated with DCX ex-
pression [79]. Importantly, we measured DCX reactivity
in the entire cell population expressing this protein, ex-
tending from proliferating progenitors to immature yet
postmitotic neurons. It is possible that stress and an-
tidepressants induce changes only in specific populations
of DCX-positive cells. Indeed, a recent study raised the
possibility of differential regulation of the distinct pop-
ulations of DCX cells by pharmacological (chronic esc-
italopram treatment) and environmental (chronic mild
stress) stimuli [82]. In particular, chronic stress was as-
sociated with less DCX-expressing postmitotic neurons,
whereas escitalopram treatment resulted in an increased
number of DCX-positive proliferating progenitors [82].
Earlier, fluoxetine had been reported to cause an in-
crease in the number of DCX-positive neuroblasts [83].
Moreover, chronic fluoxetine also accelerates the mat-
uration of DCX-positive immature neurons, as shown
by an increased number of DCX cells with more com-
plex dendritic arborization and an increased proportion
of newborn neurons that cease to express DCX marker
[84]. Based on these observations, we propose that the
chronic stress-induced decrease in the number of DCX-
expressing immature neurons is counteracted by agome-
latine which promotes the proliferating DCX-positive
cells and accelerates their progression toward postmitotic
neurons.
In summary, this study elucidated several neurobio-
logical processes targeted by agomelatine treatment in
chronically stressed rats. First, agomelatine normalized
stress-affected neuronal activity in the dentate gyrus of
the hippocampus. Second, agomelatine stimulated hip-
pocampal cell proliferation and survival under condi-
tions of chronic stress. Third, treatment with agomela-
tine reversed the stress-induced decrease in DCX expres-
sion in the dentate gyrus. Taken together, these data
indicate that agomelatine is beneficial in the stressed
brain, where it preserves the functional activity of hip-
pocampal neuronal circuitry and promotes hippocampal
neurogenesis.
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40. Lucassen PJ, Meerlo P, Naylor AS, et al. Regulation of
adult neurogenesis by stress, sleep disruption, exercise
and inflammation: Implications for depression and
antidepressant action. Eur Neuropsychopharmacol
2010;20:1–70.
41. Castren E. Neurotrophins as mediators of drug effects on
mood, addiction, and neuroprotection. Mol Neurobiol
2004;29:289–302.
42. Duman RS. Role of neurotrophic factors in the etiology
and treatment of mood disorders. Neuromolecular Med
2004;5:11–25.
43. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic
antidepressant treatment increases neurogenesis in adult
rat hippocampus. J Neurosci 2000;20:9104–9110.
44. Manev H, Uz T, Smalheiser NR, Manev R.
Antidepressants alter cell proliferation in the adult brain
in vivo and in neural cultures in vitro. Eur J Pharmacol
2001;411:67–70.
45. Madsen TM, Treschow A, Bengzon J, Bolwig TG,
Lindvall O, Tingstrom A. Increased neurogenesis in a
model of electroconvulsive therapy. Biol Psychiatry
2000;47:1043–1049.
46. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji
HK. Enhancement of hippocampal neurogenesis by
lithium. J Neurochem 2000;75:1729–1734.
47. Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A.
Agomelatine, a new antidepressant, induces regional
changes in hippocampal neurogenesis. Biol Psychiatry
2006;59:1087–1096.
48. Soumier A, Banasr M, Lortet S, et al. Mechanisms
contributing to the phase-dependent regulation of
neurogenesis by the novel antidepressant, agomelatine,
in the adult rat hippocampus. Neuropsychopharmacology
2009;34:2390–2403.
49. Trentani A, Kuipers SD, te Meerman GJ, Beekman J, ter
Horst GJ, den Boer JA. Immunohistochemical changes
induced by repeated footshock stress: Revelations of
gender-based differences. Neurobiol Dis 2003;14:
602–618.
50. Trentani A, Kuipers SD, Ter Horst GJ, Den Boer JA.
Selective chronic stress-induced in vivo ERK1/2
hyperphosphorylation in medial prefrontocortical
dendrites: Implications for stress-related cortical
pathology? Eur J Neurosci 2002;15:1681–1691.
51. Kuipers SD, Trentani A, Den Boer JA, Ter Horst GJ.
Molecular correlates of impaired prefrontal plasticity in
response to chronic stress. J Neurochem 2003;
85:1312–1323.
52. Kuipers SD, Trentani A, Westenbroek C, et al. Unique
patterns of FOS, phospho-CREB and BrdU
immunoreactivity in the female rat brain following
chronic stress and citalopram treatment.
Neuropharmacology 2006;50:428–440.
53. Dagyte G, Van der Zee EA, Postema F, Luiten PG, Den
Boer JA, Trentani A, Meerlo P. Chronic but not acute
foot-shock stress leads to temporary suppression of cell
proliferation in rat hippocampus. Neuroscience,
2009;162:904–913.
54. Westenbroek C, Den Boer JA, Veenhuis M, Ter Horst GJ.
Chronic stress and social housing differentially affect
neurogenesis in male and female rats. Brain Res Bull
2004;64:303–308.
55. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic
properties of agomelatine, an antidepressant with
melatoninergic and serotonergic properties: Role of
5-HT2C receptor blockade. Psychopharmacology (Berl),
2005;177:448–458.
56. Meerlo P, Koehl M, van der Borght K, Turek FW. Sleep
restriction alters the hypothalamic-pituitary-adrenal
response to stress. J Neuroendocrinol 2002;14:
397–402.
57. Christie BR, Cameron HA. Neurogenesis in the adult
hippocampus. Hippocampus 2006;16:199–207.
58. Dayer AG, Ford AA, Cleaver KM, Yassaee M, Cameron
HA. Short-term and long-term survival of new neurons
in the rat dentate gyrus. J Comp Neurol 2003;460:
563–572.
59. Van Der Borght K, Meerlo P, Luiten PG, Eggen BJ, Van
der Zee EA. Effects of active shock avoidance learning on
hippocampal neurogenesis and plasma levels of
corticosterone. Behav Brain Res 2005;157:23–30.
60. Scholzen T, Gerdes J. The Ki-67 protein: From the
known and the unknown. J Cell Physiol 2000;182:
311–322.
61. Rao MS, Shetty AK. Efficacy of doublecortin as a marker
to analyse the absolute number and dendritic growth of
newly generated neurons in the adult dentate gyrus. Eur
J Neurosci 2004;19:234–246.
62. Brown JP, Couillard-Despres S, Cooper-Kuhn CM,
Winkler J, Aigner L, Kuhn HG. Transient expression of
doublecortin during adult neurogenesis. J Comp Neurol
2003;467:1–10.
63. Hoffman GE, Lyo D. Anatomical markers of activity in
neuroendocrine systems: Are we all ‘fos-ed out’?
J Neuroendocrinol 2002;14:259–268.
64. Kovacs KJ. c-Fos as a transcription factor: A stressful
(re)view from a functional map. Neurochem Int
1998;33:287–297.
65. Wurtman JJ, Wurtman RJ. Fenfluramine and fluoxetine
spare protein consumption while suppressing caloric
intake by rats. Science 1977;198:1178–1180.
66. Luo SQ, Li ET. Effects of repeated administration of
serotonergic agonists on diet selection and body weight
in rats. Pharmacol Biochem Behav 1991;38:495–500.
67. Vickers SP, Dourish CT. Serotonin receptor ligands and
the treatment of obesity. Curr Opin Investig Drugs
2004;5:377–388.
68. Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM,
Wilkinson CW, Matsumoto AM, Rasmussen DD. Daily
melatonin administration to middle-aged male rats
206 CNS Neuroscience & Therapeutics 16 (2010) 195–207 c© 2010 The Authors Journal Compilation c© 2010 Blackwell Publishing Ltd
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